Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
Overview
An open label, non-comparative, multicenter, non-interventional, post marketing surveillance study to evaluate the overall safety and tolerability of pegaptanib sodium(Macugen) in the treatment of Filipino patients with neovascular age-related macular degeneration based on incidence of adverse events and to evaluate the efficacy based on visual acuity, and the patient's and physician's overall satisfaction with tolerability and efficacy.
Full Title of Study: “The Efficacy, Safety, and Tolerability of Pegaptanib Sodium in Filipino Patients With Neovascular Age-related Macular Degeneration: A Post Marketing Surveillance Study.”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: May 2009
Detailed Description
Open-label, non-comparative, non-interventional study
Interventions
- Drug: Macugen
- Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
Arms, Groups and Cohorts
- Phase IV Post Marketing Surveillance Study
- Open-label, observational study
Clinical Trial Outcome Measures
Primary Measures
- Incidence of adverse events and serious adverse events
- Time Frame: 12 months
Secondary Measures
- Mean change in visual acuity in the study eye at 6 months from baseline
- Time Frame: 6 months
Participating in This Clinical Trial
Inclusion Criteria
- Must have at least one eye which was diagnosed with neovascular degeneration Exclusion Criteria:
- Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, multifocal choroiditis
Gender Eligibility: All
Minimum Age: 50 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Pfizer
- Provider of Information About this Clinical Study
- Director, Clinical Trial Disclosure Group, Pfizer, Inc.
- Overall Official(s)
- Pfizer CT.gov Call Center, Study Director, Pfizer
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.